diabetestalk.net

Clinical Features And Treatment Of Maturity Onset Diabetes Of The Young (MODY)

Clinical features and treatment of maturity onset diabetes of the young (MODY)

Clinical features and treatment of maturity onset diabetes of the young (MODY)


Clinical features and treatment of maturity onset diabetes of the young (MODY)
1Department of Endocrinology, Singapore General Hospital, Singapore
2Department of Endocrinology, National University Hospital, Singapore
Correspondence: Daphne SL Gardner, Department of Endocrinology, Singapore General Hospital, Block 6, Level 6, Outram Road, Singapore 169608, Tel +65 6321 4523, Email [email protected]
Author information Copyright and License information Disclaimer
Copyright 2012 Gardner and Tai, publisher and licensee Dove Medical Press Ltd.
This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
This article has been cited by other articles in PMC.
Maturity onset diabetes of the young (MODY) is a heterogeneous group of disorders that result in -cell dysfunction. It is rare, accounting for just 1%2% of all diabetes. It is often misdiagnosed as type 1 or type 2 diabetes, as it is often difficult to distinguish MODY from these two forms. However, diagnosis allows appropriate individualized care, depending on the genetic etiology, and allows prognostication in family members. In this review, we discuss features of the common causes of MODY, as well as the treatment and diagnosis of MODY.
Keywords: type 1 diabetes, type 2 diabetes, HNF1A, HNF4A, HNF1B, GCK
Maturity onset diabetes of the young (MODY) was a term first used in the 1970s 1 , 2 to describe inheritable diabetes distinct from type 1 (insulin-dependent) and type 2 (noninsulin-dependent) diabetes. In these initial reports, MODY patient Continue reading

Rate this article
Total 1 ratings
Weed and Diabetes : Marijuana

Weed and Diabetes : Marijuana


Don't post Blogspam. Use a Primary Source.
No spam or blog spam. Articles should have original content. Articles that just link to other articles with no original content will be removed.Blog Spam is an Article/Page that simply directly copies other people's work, with or without a direct citation. This is different from an article that is creating new content and citing sources to support its content.Essentially, like a college essay: These submission can agree AND cite as many points as it would like, but only if new information is added to support an original point or statement.
No flaming, name calling, bullying, trolling or inciting unmerited arguments.Discuss your point, but be civil about it. No attacks, please utilize down-votes as a form of community moderation, not for disagreement. IF you see someone doing this, please message the mods.
No "ID this for me" threads, "How to avoid drug test" threads, "where can I find x or x that deals x" threads. This subreddit does not exist to help you locate or identify Marijuana, nor does it exist to help you pass drug tests.
We encourage the use of informative images, infographics, gifs, and video. This is an educational / informative subreddit. Please keep any images relevant to the subreddit. Keep it classy. No "stash" pictures.
No editorialized or misleading titles; and also, no articles that claim to be factual yet lack sound sources or evidence accepted by the academic community. Please read your submission before you submit!
No same-week reposts. Reposts, double posts, etc: When a story is very popular, we Continue reading

Postmenopausal Night Sweats Tied to Diabetes Risk

Postmenopausal Night Sweats Tied to Diabetes Risk


Postmenopausal Night Sweats Tied to Diabetes Risk
Women who have postmenopausal vasomotor symptoms (VMS), especially night sweats, have a higher risk for type 2 diabetes, according to a study published December 6 in Menopause. Further, the excess risk increased with the severity and duration of women's symptoms, the researchers found.
"The most plausible and consistent explanation may be through associations with sleep disturbance," write Kristen E. Gray, PhD, from the Veterans Affairs Puget Sound Health Care System and the University of Washington School of Public Health in Seattle, and colleagues. "VMS overall are associated with objective and subjective sleep disturbance, and individuals with disruptions in both the quantity and quality of sleep have a higher risk of diabetes."
Sleep, then, may mediate associations between VMS and diabetes, they add.
"In particular, night sweats are more strongly associated with sleep disturbance than hot flashes, as they occur during the night, which may explain their more pronounced relationship with diabetes," the authors write. "Our results also suggest that night sweats or their effects may be largely responsible for the association between VMS overall and diabetes."
The researchers prospectively tracked and analyzed data for 150,007 postmenopausal women participating in the Women's Health Initiative study to explore possible associations between incident diabetes and VMS from 1993 to 2014. In addition to looking at the severity of hot flashes and night sweats, the researchers looked at the timing of symptoms and how long the Continue reading

Age At Menopause and Type 2 Diabetes Risk

Age At Menopause and Type 2 Diabetes Risk


Home / Conditions / Type 2 Diabetes / Age At Menopause and Type 2 Diabetes Risk
Age At Menopause and Type 2 Diabetes Risk
Early onset menopause linked to increased risk of type 2 diabetes in a cohort study.
Menopause is a universal phenomenon that all women will eventually experience after a certain age. This major life transition is due to the ovaries cessation of estrogen and progesterone production. The age at which menopause occurs varies greatly from woman to woman, however the age of final menstruation is key to predicting health outcomes. Later age of natural menopause is associated with reduced morbidity and mortality, reduced risk of cardiovascular disease and complications, reduced risk of osteoporosis and fracture and overall better quality of life. The average age of menopause in the United States is 51 years old, with premature menopause being defined by final menstruation before the age of 40. Menopause is associated with weight gain, impaired glucose homeostasis, and an increase in visceral fat; all major risk factors for the development of type 2 diabetes.
Type 2 diabetes is a major risk factor for cardiovascular disease, however, it is unclear if menopause is associated with the risk of developing type 2 diabetes. Animal studies have shown that estradiol decreases the amount of adipose tissues and has a protective role in the metabolism of glucose. Other trials have also shown that postmenopausal women on oral estrogen therapy have a decreased risk of developing type 2 diabetes. Therefore, the aim of this study was to investigate the association betwe Continue reading

Bart Roep, Ph.D., Has Type 1 Diabetes Cure in His Sights

Bart Roep, Ph.D., Has Type 1 Diabetes Cure in His Sights


Bart Roep, Ph.D., Has Type 1 Diabetes Cure in His Sights
Bart O. Roep, Ph.D., has dedicated his life to the search for a cure for type 1 diabetes. And he thinks he is on the brink.
Roep, an internationally renowned immunologist who joined City of Hope last year from the Netherlands Leiden University Medical Center, was recently named the Chan Soon-Shiong Shapiro Distinguished Chair in Diabetes. He believes that this endowment and a $50 million funding project led by the Wanek family will be key in stopping the disease.
We need to do something in addition to treating the symptoms, Roep said. Diabetes has surpassed cancer as a cause of death. One of the goals of the diabetes program at City of Hope is to accelerate the progress against the disease. And the new $50-million grant is a catalyst to get there faster.
Instead of dealing with the effects of the disease, Roep is committed to treating the disease itself.
For 100 years, weve known how to deal with the symptoms, he said. Now, for the first time, we can tackle the cause. This is really one of the most exciting times since the discovery of insulin. We have the opportunity to offer a completely new generation of therapy to these patients.
After studying the mechanism of type 1 diabetes for the last two decades, Roep, the founding chair of the DepartmentofDiabetesImmunology within the Diabetes&MetabolismResearchInstituteatCityofHope , recently had his Eureka! moment when he realized that the disorder varies greatly from patient to patient.
One of the new insights is that diabetes is very diverse, he said. Based on Continue reading

No more pages to load

Popular Articles

Related Articles